The stock was up 0.7% to $160.69 ... Rybrevant plus Lazcluze for the treatment of patients with non-small cell lung cancer. This approval came after a Phase 3 study showed the combination reduced ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...

The Akeso (OTCPK:AKESF)-sponsored trial was designed to evaluate ivonescimab against Merck’s (NYSE:MRK) Keytruda (pembrolizumab) in certain patients with non-small cell lung cancer (NSCLC).